Emerging technologies in autoantibody testing for rheumatic diseases

Nancy J. Olsen, May Y. Choi, Marvin J. Fritzler

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations


Testing for the presence of antinuclear antibodies (ANAs) is a key step in the diagnosis of systemic lupus erythematosus (SLE) and other systemic autoimmune rheumatic diseases (SARD). The standard slide-based indirect immunofluorescence (IIF) test is widely used, but is limited by a relative lack of specificity for SLE and not all SARD-ANAs are detected. Alternative immunoassays that might offer enhanced diagnostic and prognostic information have evolved, and some of these have entered clinical practice. This review summarizes the current state of ANA testing and multiplex techniques for detecting other autoantibodies, the possibility of point-of-care testing, and approaches for applications in early disease stages.

Original languageEnglish (US)
Article number172
JournalArthritis Research and Therapy
Issue number1
StatePublished - Jul 24 2017

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Emerging technologies in autoantibody testing for rheumatic diseases'. Together they form a unique fingerprint.

Cite this